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Abstract
Background: The efficacy and tolerability of 500-730 kDa sodium hyaluronate (Hyalgan
®) for treatment of
osteoarthritis (OA) pain has been established in clinical trials, but few data are available in the Asian population. We
conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and
tolerability of this preparation in a Taiwanese population.
Methods: Two hundred patients with mild to moderate OA of the knee were randomized to receive five weekly
intra-articular injections of sodium hyaluronate or placebo. The primary efficacy outcome was the change from
baseline to Week 25 in patients’ evaluation of pain using a 100-mm visual analog scale (VAS) during the 50-foot
walking test. Additional outcomes included Western Ontario and McMaster Universities (WOMAC) scores, time on
the 50-foot walking test, patient’s and investigator’s subjective assessment of effectiveness, acetaminophen
consumption, and the amounts of synovial fluid.
Results: The Hyalgan
® treatment group showed a significantly greater improvement from baseline to Week 25 in
VAS pain on the 50-foot walking test than the placebo group (p = 0.0020). The Hyalgan
® group revealed
significant improvements from baseline to week 25 in WOMAC pain and function score than the placebo group (p
= 0.005 and 0.0038, respectively) Other outcomes, such as time on the 50-foot walking test and subjective
assessment of effectiveness, did not show any significant difference between groups. Both groups were safe and
well tolerated.
Conclusions: The present study suggests that five weekly intra-articular injections of sodium hyaluronate are well
tolerated, can provide sustained relief of pain, and can improve function in Asian patients with osteoarthritis of the
knee.
Level of Evidence: Therapeutic study, Level I-1a (randomized controlled trial with a significant difference).
Trial registration: ClinicalTrials.gov Identifier: NCT01319461
Background
Osteoarthritis (OA) of the knee is a common arthropa-
thy and a leading cause of disability in elderly adults.
The disease is characterized by a reduction in the lubri-
cating and viscoelastic properties of the synovial fluid,
accompanied by progressive destruction of the cartilage
surface [1,2]. When simple analgesics, such as acetami-
nophen, prove ineffective for reducing the pain of OA,
the most common therapy for treating the signs and
symptoms of OA is nonsteroidal anti-inflammatory
drugs (NSAIDs). NSAIDs have proven efficacy for the
relief of pain and inflammation of OA, but their use
may be restricted by adverse gastrointestinal effects,
including serious occurrences of bleeding [3,4].
Hyaluronic acid present in the synovial fluid and carti-
lage of the knee imparts viscoelastic properties that
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any medium, provided the original work is properly cited.allow for the efficient movement of articular joints [5].
Hyalgan
® (Fidia, S.p.A., Abano Terme, Italy) is a sodium
hyaluronate preparation, with a molecular weight of
500-730 kDa, which is naturally derived from rooster
combs and has the same molecular structure as the
endogenous hyaluronic acid present in the human body
[6]. This sodium hyaluronate restores the viscoelastic
properties of the synovial fluid and stimulates synthesis
of endogenous hyaluronic acid by synoviocytes [7,8]. In
addition, this sodium hyaluronate may also mediate
therapeutic effects in OA by a number of other bio-
chemical actions within the joint, including the induc-
tion of proteoglycan aggregation and proteoglycan
synthesis, inhibition of inflammatory mediators, and
analgesic activity [9].
The efficacy and tolerability of intra-articular (i.a.)
injections of this sodium hyaluronate have been estab-
lished in many clinical trials conducted worldwide
[10-18]. In a large, controlled clinical trial conducted in
the United States, a 5-injection course of sodium hyalur-
onate was shown to provide effective pain relief for as
long as 26 weeks after initiation of the therapeutic
course [10]. Accordingly, i.a. injections of sodium hya-
luronate are considered by the American College of
Rheumatology (ACR) to be an alternative to NSAIDs for
treatment of pain in patients with OA [4]. Hyalgan
® was
approved by the United States Food and Drug Adminis-
tration in 1997, and this therapeutic agent is now avail-
able in over 43 countries worldwide. However, only one
study has been published evaluating this sodium hyalur-
onate in an Asian population; these investigators found
that 4 weekly doses decreased pain and increased mobi-
lity over a 49-day follow-up [19]. The primary purpose
of this study was to evaluate the efficacy and tolerability
of this 20-mg/2 mL sodium hyaluronate administered as
5 i.a. injections at weekly intervals, for relieving the pain
of OA of the knee in the Asian population.
Methods
Patients
Patients eligible for the study were males or females >
50 years of age, diagnosed with OA of the knee accord-
ing to ACR criteria (knee pain with one or more of the
following conditions: age > 50 years, crepitus, or morn-
ing stiffness < 30 minutes in duration). Eligible patients
also had radiographic evidence of OA with Kellgren-
Lawrence score of II to III (mild to moderate) on x-ray,
with predominance in the tibio-femoral compartment
and visual analog scale (VAS) pain scores of ≥ 40 mm
on a 50-foot walking test. It was required that any acute
disease or trauma leading to secondary OA must have
occurred at least 5 years before study entry. Major
exclusion criteria included severe degeneration of the
knee joint with marked joint narrowing, varus, or valgus
deformity of the knee (> 12°) or other joint deformities,
or other joint disorders (eg, inflammatory joint disease,
specific arthropathy, severe axis deviations or instabil-
ities, joint or skin infections, joint prostheses of the
lower limbs or symptomatic hip). Patients were not per-
mitted to have received i.a. steroid injections within the
2 weeks prior to study entry.
Study design
Ethical approval has been granted by Ethics Committee
of Department of Health, Taiwan (Ref: DOH-TW-
0890036458) and the participating medical centers,
including National Taiwan University Hospital, the Tai-
pei Medical College Hospital, and the Tri-Service Gen-
eral Hospital, in Taipei, Taiwan.
This was a prospective, randomized, masked-observer,
double-blind, parallel group, placebo-controlled study
designed to evaluate the efficacy and safety of 5 weekly
i.a. injections of sodium hyaluronate (Hyalgan
®,F i d i aS .
p.A, Abano Terme, Italy) at 20 mg/2 mL in comparison
with 5 weekly i.a. injections of saline placebo (2 mL) in
patients with radiographically confirmed, mild to moder-
ate OA of the knee. The study was conducted at 3 hos-
pitals: the National Taiwan University Hospital, the
Taipei Medical College Hospital, and the Tri-Service
General Hospital, in Taipei, Taiwan. Six investigators
enrolled patients. Efficacy was defined as improvement
from baseline to Week 25 after initiation of treatment in
100-mmVAS pain on the 50-foot walking test. After a
screening period, eligible patients were randomized to 5
weekly injections with either sodium hyaluronate or pla-
cebo, and were then evaluated at Week 5, Week 13, and
Week 25. Patients who required further pain treatment
were permitted to take acetaminophen as needed, but
not exceeding 3 g/day. Patients were not permitted to
take any acetaminophen on the day before the study
visit. Oral and parenteral corticosteroids, i.a. corticoster-
oid injections, NSAIDs or analgesics other than acetami-
nophen, topical analgesic preparations, rehabilitation,
physical therapy, or acupuncture were not permitted
during the study.
Definition of the primary outcome and the secondary
outcome
The primary efficacy outcome was defined as the change
from baseline (Week 0) to Week 25 in patients’ evalua-
tion of pain, measured by a 100-mm VAS during the
50-foot walking test (0 = “No Pain” and 100 = “Maxi-
mum Pain”). The secondary efficacy measures included:
(1) the Western Ontario and McMaster Universities
(WOMAC) OA scales for pain, stiffness, and physical
function, by VAS; (2) time taken in the 50-foot walking
test; (3) volume of synovial effusion of the enrolled
knee, if present; (4) overall effectiveness evaluated by
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Gravely worsened and 6 = Excellent improved); and 5)
acetaminophen tablet count.
Sample Size
The sample size required was estimated based on results
from the UK study conducted by Huskisson and Don-
nelly, in which the adjusted means difference between
treatment groups for VAS pain on movement at 6
months was equal to 15.04 mm, and the corresponding
effect size was equal to 0.52 for completers [18]. Sixty
patients in each group were required to ensure adequate
power to detect a similar between-groups difference.
Statistical Analysis
Treatment groups were compared with respect to the
primary efficacy variable using an analysis of variance,
including treatment, investigator, and treatment-by-
investigator interaction as factors. The analysis was
based on the intent-to-treat (ITT) population with the
last observation carried forward (LOCF) for patients
who did not complete the study. Improvement in
WOMAC index and improvement in time taken for the
50-foot walking test were analyzed using the same
approach as for the primary variable. Volume of synovial
fluid effusion was evaluated using the student’st - t e s t .
Patients’ and investigators’ overall effectiveness evalua-
tions were analyzed by Chi-square test. Between-group
comparison for acetaminophen consumption was con-
ducted using the Wilcoxon rank sum test.
Safety
Safety was assessed by adverse events, laboratory find-
ings, and vital signs.
Results
Patient Characteristics and Disposition
Of 227 patients screened, 200 patients were randomized
in the study. Of these, 176 patients completed the study,
and 198 patients (100 in the sodium hyaluronate group,
98 in the placebo group) were included in the ITT
population. Of the 24 patients who withdrew from the
study, 2 were lost to follow-up, 7 withdrew due to lack
of efficacy, and 15 withdrew consent. The flow of study
participants is shown in Figure 1.
D e m o g r a p h i ca n db a s e l i n ec h a r a c t e r i s t i c so ft h es t u d y
population are shown in Table 1. Mean age of the patients
in both treatment groups was 65.0 years. The two treat-
ment groups were similar with regard to all demographic
and baseline disease characteristics evaluated. There were
no significant differences between the treatment groups
with regard to baseline VAS scores on the 50-foot walking
test or any of the other measures of pain and function.
Primary Efficacy Outcome
Concerning the placebo group, the VAS scale was
improved from baseline (Week 0) of 45.15 mm to 21.53
mm (Week 25). As to Hyalgan treatment group, the
VAS scale was improved from 47.85 (Week 0) to 17
mm (Week 25). The difference of VAS scale at week 25
between these two groups was statistically significant
(17 mm versus 21.53 mm for Hyalgan and placebo,
respectively) (p = 0.035). (Table 2) The Hyalgan treat-
ment group showed a significantly greater improvement
from baseline to Week 25 in VAS pain on the 50-foot
walking test than the placebo group (reduction of 30.85
mm versus 23.62 mm for Hyalgan and placebo, respec-
tively; and, least squares mean difference between
groups of 8.07 ± 2.58 mm, 95% CI 2.98-13.16 mm, p =
0.002). (Table 2) The reduction in pain intensity as
compared with baseline (week 0) was apparent at one
week after the first dose (reduction of 9.9 ± 12.33 mm
versus 7.55 ± 8.95 mm for sodium hyaluronate and pla-
cebo, respectively). However, the difference between
groups became significant only after completion of the
5-injection treatment course (Week 5) (p = 0.026). (Fig-
ure 2) The detailed VAS scales at different period were
shown in Table 2. The Mean changes of VAS scale
from baseline (W0) in both groups were presented in
Figure 2.
Secondary Efficacy Outcomes
WOMAC scores
Both the sodium hyaluronate and placebo groups
showed improvement in the secondary efficacy para-
meters of WOMAC pain, stiffness, and function
scores over the 25-week study period. The sodium
hyaluronate group revealed significant improvements
from baseline to week 25 in WOMAC pain and func-
tion score than the placebo group (p = 0.0050 and
0.0038, respectively) Although there was a greater
improvement in sodium hyaluronate-treated patients
for the parameter of WOMAC stiffness throughout
the 25-week follow-up period, this difference did not
achieve statistical significance at any timepoint.
(Table 3) The between-group mean difference for
WOMAC pain scores was significant in favor of
sodium hyaluronate as early as Week 5 (p = 0.023)
(Figure 3). Similarly, patients treated with sodium
hyaluronate showed significantly greater improvement
in WOMAC function scores as early as the end of the
5-injection treatment course (Week 5) (p = 0.0081)
(Figure 4).
Time on the 50-foot walking test
Both treatment groups showed a slight reduction in
time consumed on the 50-foot walking test with no sta-
tistically significant difference between them.
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N o m i n a l l ym o r ep a t i e n t si nt h es o d i u mh y a l u r o n a t e
group compared with the placebo group were consid-
ered “slightly improved”, “improved”,o r“excellent
improved” by both patient’s judgment of effectiveness
at Week 25 (58 versus 45 patients, respectively) and
investigator’s judgment (60 versus 47 patients,
respectively). On the other hand, less patients in the
sodium hyaluronate group compared with the pla-
cebo group were considered “slightly worsened” or
“gravely worsened” at Week 25 by both patient’s
judgment (6 versus 15 patients, respectively) and
investigator’s judgment (7 versus 14 patients, respec-
tively). However, the differences did not achieve
significance.
Acetaminophen consumption
There was no statistically significant difference between
the treatment groups with regard to the total mean acet-
aminophen consumption over the 25-week study period.
Synovial fluid volume
The amounts of synovial fluid drawn at each timepoint
through Week 25 were similar in these two groups,
either for the entire treatment population or when the
analysis was only applied to patients with the volume of
synovial fluid > 0.
Safety
There were a total of 153 adverse events (67 in the
sodium hyaluronate groups, 86 in the placebo group)
reported by 87 patients. More patients in the placebo
Figure 1 Flow of study participants.
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experienced at least 1 adverse event (48% versus 39%).
The nature of adverse events reported was comparable
between these two treatment groups. All reported events
were mild or moderate in intensity, and none were con-
sidered related to study treatment. The most frequently
reported adverse events in both treatment groups were in
the respiratory system, the most common of which were
acute bronchitis and bronchitis combined, occurring in a
total of 10 patients in the study. No patients discontinued
from the study because of an adverse event. Five serious
adverse events were reported in the study: 3 in the
sodium hyaluronate group and 2 in the placebo group.
These included a forearm fracture, intestinal obstruction,
and aggravated urinary incontinence in the sodium hya-
luronate group, and upper gastrointestinal bleeding and
joint sprain in the placebo group. All were considered to
be unrelated to study treatment.
A statistically significant treatment difference was seen
in change from baseline for platelet counts at Week 5 (p
= 0.027), with standardized counts decreasing slightly in
the sodium hyaluronate group and increasing slightly in
the placebo group. However, this difference was not
considered clinically relevant nor was it apparent at
other timepoints during the study. No other significant
laboratory results or vital signs findings were observed.
Power of the Current Trial
Based on the current observed results of primary out-
come (change from W0 to W25) and the sample size
for each group, this study give a power of 91.3% to iden-
tify the change in VAS score between groups.
Discussion
Hyaluronan (HA), a large glycosaminoglycan composed
of repeating disaccharides of D-glucuronic acid and N-
acetyl-glucosamine, is a ubiquitous component of the
extracellular matrix. Intra-articular (i.a.) injection of HA
is now applied worldwide for the treatment of arthritis.
The efficacy and tolerability of i.a. injections of
Table 1 Baseline demographics and disease characteristics of all randomized patients
Total (n = 200) Hyalgan
® (n = 100) Placebo (n = 100) p value
Demographic Characteristic
Age, mean (SD), yrs 65.0 (8.3) 65.9 (8.1) 64.2 (8.4) NS
Sex, n (%)
Male 48 (24.0%) 26 (26.0%) 22 (22.0%) NS
Female 152 (76.0%) 74 (74.0%) 78 (78.0%) NS
Weight, mean (SD), kg 62.7 (10.2) 63.3 (11.9) 62.1 (8.3) NS
Height, mean (SD), cm 156.5 (7.2) 156.8 (7.7) 156.3 (6.7) NS
BMI, mean (SD), kg/m
2 25.6 (3.6) 25.7 (4.3) 25.4 (2.9) NS
Disease Characteristic
Kellgren-Lawrence grade
Grade II (mild), n (%) 119 (59.5%) 59 (59.0%) 60 (60.0%) NS
Grade III (moderate), n (%) 81 (40.5%) 41 (41.0%) 40 (40.0%) NS
Duration of OA, mean (SD), days 427.0 (1022.5) 499.2 (1190.8) 354.8 (820.5) NS
Clinical Evaluation
Pain on 50-foot walking test (VAS 0-100 mm) mean (SD) 46.75 (10.59) 47.85 (10.76) 45.65 (10.36) NS
WOMAC A-pain (VAS 0-100 mm) mean (SD) 45.56 (12.12) 45.73 (11.17) 45.39 (13.06) NS
WOMAC C-function(VAS 0-100 mm) mean (SD) 45.99 (12.23) 46.54 (11.31) 45.45 (13.13) NS
SD, standard deviations.
NS, non-significantly different between treatment groups (P > 0.05)
Table 2 The VAS pain scales of Placebo and Hyalgan treatment groups on the 50-foot walking test
Week (W) Hyalgan
® (n = 100) VAS (mm) Placebo (n = 98) VAS (mm) p value
Baseline (W0) 47.85 ± 10.76 45.15 ± 9.75 0.066
W25 17.00 ± 14.32 21.53 ± 15.69 0.035*
Change from W0 to W1 9.9 ± 12.33 7.55 ± 8.95 0.127
Change from W0 to W5 24.75 ± 12.66 20.41 ± 15.38 0.026
Change from W0 to W13 27.27 ± 14.97 24.01 ± 16.95 0.076
Change from W0 to W25 (Primary Outcome) 30.85 ± 14.16 23.62 ± 16.38 0.002**
VAS pain scales were shows as mean ± SD.
*P < 0.05, **P < 0.01, indicated significantly different between treatment groups.
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® have been established in many clinical trials
conducted worldwide [10-19]. However, little study has
specially addressed in evaluating the effect and safety of
this sodium hyaluronate on an Asian population.
The primary aim of this clinical trial was to study the
efficacy and safety of 5 weekly i.a. injections of sodium
hyaluronate (Hyalgan
®), as compared with the placebo,
in Asian patients suffering from OA of the knee. The
duration of this study comprised a 5-week treatment
period followed by a 20-week follow-up period. The
results demonstrate that the Hyalgan treatment group
showed a significantly greater improvement from base-
line to Week 25 in VAS pain on the 50-foot walking
test than the placebo group. Our findings were further
supported by a previous pivotal clinical trial involving
218 completed patients (103 for Hyalgan
® versus 115
for placebo) [10]. At Week 26 of follow-up, the statisti-
cally significant treatment difference for pain intensity
on the 50-foot walking test (assessed by a 0-100 mm
VAS) was 8.8 mm in favor of sodium hyaluronate, simi-
lar to the magnitude of effect seen here (8.07 mm).
Their sample size and the result of VAS difference are
quite comparable to our study. That means the current
study provide a similar power as theirs. As to the sam-
ple size and the accepted absolute changes of VAS, Hus-
kisson [18] conducted a randomized control trial to
examine the efficacy, safety and patient satisfaction of i.
a.HA in patients with osteoarthritis of the knee. They
used a sample size of 50 patients for each group to give
a power of around 90% for the detection of a mean
treatment change of 15.4 mm in VAS score. In the cur-
rent study, our sample size is 100 patients for each
g r o u pt h a tp r o v i d eas i m i l a rp o w e ro f9 1 . 3 %f o rt h e
detection of mean treatment change of 8.07 mm in VAS
score.
In the present study, the reduction in pain intensity
was apparent at one week after the first dose of sodium
hyaluronate. This finding was further confirmed by
Figure 2 Mean change from baseline in VAS pain on the 50-
foot walking test. The primary efficacy outcome of change from
baseline through Week 25 measured by VAS pain score (0-100 mm
scale) on the 50-foot walking test for the ITT population (sodium
hyaluronate, n = 100; placebo, n = 98).
Table 3 Mean change from baseline to Week 25 in
WOMAC index scores
WOMAC section Hyalgan
®
(n = 100)
Placebo
(n = 98)
p value
Pain
Change from W0 to W25, mm (SE) 29.28 (1.92) 21.52 (1.94) 0.0050*
Stiffness
Change from W0 to W25, mm (SE) 24.85 (2.18) 22.58 (2.21) 0.4640
Function
Change from W0 to W25, mm (SE) 25.16 (1.67) 18.20 (1.69) 0.0038*
SE, standard error of mean.
*P < 0.05, indicated significantly different between treatment groups.
Figure 3 Mean change from baseline (mm) in WOMAC pain
scores. Patients treated with sodium hyaluronate exhibited
statistically significant improvement in WOMAC pain indices as
compared with placebo treatment. Data are shown for the ITT
population.
Figure 4 Mean change from baseline (mm) in WOMAC function
scores. Patients treated with sodium hyaluronate exhibited
statistically significant improvement in WOMAC function indices as
compared with placebo treatment. Data are shown for the ITT
population.
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randomized, multicentre clinical trial to compare the
clinical effects between high and low molecular weight
HA. They indicated that the symptom relief could be as
soon as one week after HA injection, in terms of signifi-
cantly reducing the VAS and improving the WOMAC
pain, function, and stiffness scores. A similar finding
was shown in another clinical trial by Kirchner M [21].
We may attribute the rapid reduction in pain intensity
to the mechanism of anti-inflammation through the
synovium, which was further supported by a recent
review article [22].
Regarding the secondary outcome estimated by
WOMAC scores, we found that the pain and function
sub-scales were significantly reduced as early as at Week
5, by compared with placebo group. Furthermore, the
significant difference was maintained throughout the
study. As to the subjective evaluations, more patients in
the sodium hyaluronate group compared with the pla-
cebo group were considered “slightly improved”,
“improved”,o r“excellent improved” by both patient’s
and investigator’s judgment of effectiveness at Week 25.
These results all imply that i.a. administration of Hyal-
gan
® can improve joint function and ameliorate pain in
Asian patients with knee osteoarthritis.
Concerning the estimation of safety, both sodium hya-
luronate and placebo were well tolerated in this study.
There were no instances of any severe local inflamma-
tory reactions, such as have been reported with growing
frequency in the literature for another hyaluronate pro-
duct, hylan G-F 20 [23]. Aside from an apparently iso-
lated difference between the treatment groups in platelet
counts at Week 5 (not clinically significant), no changes
in laboratory values, blood pressure, pulse rate, or body
temperature were observed in either treatment group.
In the present study, efficacy of sodium hyaluronate,
as measured by the primary outcome variable, did not
show signs of waning at the 25-week timepoint. There-
fore, we might have seen a longer-term benefit of this
sodium hyaluronate had the follow-up period been
extended. This finding of a relatively long-term pain
relief is also consistent with findings of controlled and
uncontrolled clinical trials that found continuing bene-
fits with sodium hyaluronate treatment for at least 6
months [18] and, in some cases, for 1 or more years
after completion of the treatment course [16,24,25].
To sum up, our results showed that a 5-injection
course of this sodium hyaluronate was effective, in
terms of a significantly greater improvement from base-
line to Week 25 in VAS score, WOMAC pain and func-
tion score than the placebo group. The whole course
was safe and well tolerated both in sodium hyaluronate
treatment group and the placebo.
Conclusion
T h ep r e s e n ts t u d yd e m o n s t r a t e dt h a ti n t r a - a r t i c u l a r
administration of Hyalgan
® is safe and can improve
joint function and ameliorate pain in Asian patients
with knee osteoarthritis.
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